compared with Bascom's procedure (mean difference (MD) -2.50, 95% confidence interval (CI) -4.03 to -0.97) (evidence downgraded twice for risk of performance and detection bias). Fibrin glue may reduce the time taken to return to normal activities compared with Bascom's procedure (mean time 42 days with surgery and 7 days with glue, MD -34.80 days, 95% CI -66.82 days to -2.78 days) (very low-quality evidence, downgraded as above and for imprecision).
Fibrin glue as an adjunct to the Limberg flap may reduce the healing time from 22 to 8 days compared with the Limberg flap alone (MD -13.95 days, 95% CI -16.76 days to -11.14 days) (very low-quality evidence, downgraded twice for risk of selection, performance and detection bias and imprecision). It is uncertain whether use of fibrin glue affects the incidence of postoperative seroma (an adverse event) (risk ratio (RR) 0.27, 95% CI 0.05 to 1.61; very low-quality evidence, downgraded twice for risk of selection, performance and detection bias and imprecision). There was low-quality evidence that fibrin glue, as an adjunct to Limberg flap, may reduce postoperative pain (median 2 versus 4; P < 0.001) and time to return to normal activities (median 8 days versus 17 days; P < 0.001). The addition of fibrin glue to the Limberg flap may reduce the length of hospital stay (MD -1.69 days, 95% CI -2.08 days to -1.29 days) (very lowquality evidence, downgraded twice for risk of selection, performance and detection bias and for unexplained heterogeneity).
A single RCT evaluating fibrin glue as an adjunct to the Karydakis flap did not report data for the primary outcome of time to healing. It is uncertain whether fibrin glue with the Karydakis flap affects the incidence of postoperative seroma (adverse event) (RR 3.00, 95% CI 0.67 to 13.46) (very low-quality evidence, downgraded twice for risk of selection, performance and detection bias and for imprecision). Fibrin glue as an adjunct to Karydakis flap may reduce length of stay but this is highly uncertain (mean 2 days versus 3.7 days; P < 0.001, low-quality evidence downgraded twice for risk of selection, performance and detection bias).
Authors' conclusions
Current evidence is uncertain regarding any benefits associated with fibrin glue either as monotherapy or as an adjunct to surgery for people with pilonidal sinus disease. We identified only four RCTs and each was small and at risk of bias resulting in very low-quality evidence for the primary outcomes of time to healing and adverse events. Future studies should enrol many more participants, ensure adequate randomisation and blinding, whilst measuring clinically relevant outcomes.
P L A I N L A N G U A G E S U M M A R Y

Fibrin glue for pilonidal sinus disease
Review question
We reviewed the evidence regarding the effectiveness of fibrin glue, used on its own or with surgery, in the treatment of pilonidal sinus disease.
Background
Pilonidal sinus disease is a common condition mainly affecting young adults. The condition develops following an infection in the groove between the buttocks. The infection can cause fluid collections or a sinus (a channel under the skin) to form. Young men are more likely to be affected, and other risk factors include obesity, poor hygiene and prolonged sitting. Extensive body hair is also a factor as ingrowing hair follicles are thought to make the condition worse. The condition causes pain and often requires time off work. This affects patients' quality of life and may cause loss of earnings.
Pilonidal sinus disease is normally treated with a small operation. Fibrin glue, a naturally-occurring glue-like gel, can also be used as an alternative to, or in addition to surgery. We looked for evidence as to whether fibrin glue can speed up the healing time for this type of wound. We also wanted to find out if the treatment affected other outcomes such as pain, infection and return of the pilonidal sinus following the procedure, and whether it had any side effects (fluid collections or allergic reactions).
Study characteristics
In December 2016 we searched for randomised controlled trials involving participants of any age or sex, whose pilonidal sinus had been treated with fibrin glue, either on its own or with surgery. We found four studies that included 253 participants, the majority of whom were male. Fibrin glue on its own was compared with surgery in one study. In three studies fibrin glue was applied during surgery and compared with surgery on its own. There were problems with the design and conduct of all four studies which mean that their results are very uncertain.
It is not known whether fibrin glue on its own affects time to healing and adverse events compared with a type of surgery (Bascom's procedure). Fibrin glue may result in less pain on the first day after the procedure compared with Bascom's procedure.
When fibrin glue is used alongside a type of surgery called the Limberg flap it may reduce the healing time by approximately 14 days compared with the surgery on its own, however this finding is highly uncertain as the evidence is very low-quality. It is uncertain whether using the fibrin glue alongside the Limberg flap affects the incidence of a complication called seroma (a collection of fluid) but it may reduce postoperative pain (this evidence is low-quality and therefore quite uncertain) and may reduce time to return to normal activities (low-quality evidence) and length of hospital stay (this was very low-quality evidence and therefore very uncertain).
One study evaluated the effect of adding fibrin glue to a type of surgery called the Karydakis flap. It is not clear from this study whether using the glue affects time to healing or the incidence of seroma. Using the fibrin glue with the Karydakis flap may reduce length of hospital stay compared with surgery alone but again this is low-quality evidence.
Quality of the evidence
The quality of evidence for all outcomes was low or very low, mainly due to problems with the ways the studies were conducted and also the uncertainty in the results because of the small numbers of participants in the studies. This means we cannot be confident of the effects of fibrin glue on any of these outcomes and more, better quality and larger studies are required.
This plain language summary is up to date as of December 2016.
S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Fibrin glue compared with Bascom's procedure for pilonidal sinus Not reported GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our conf idence in the estim ate of ef f ect. M oderate quality: Further research is likely to have an im portant im pact on our conf idence in the estim ate of ef f ect and m ay change the estim ate. Low quality: Further research is very likely to have an im portant im pact on our conf idence in the estim ate of ef f ect and is likely to change the estim ate. Very low quality: We are very uncertain about the estim ate.
B A C K G R O U N D
Description of the condition
Pilonidal sinus disease is a common condition and mainly affects young adults. The term pilonidal derives from the Latin words for hair (pilus) and nest (nidus) and was first described by Mayo in 1833 (Mayo 1833). Pilonidal sinus is an acquired disease, which results in obstruction of hair follicles in the natal cleft (the anatomical groove between the buttocks), a commonly affected area. Subsequent rupture of the follicles leads to abscess and sinus formation. This condition is further exacerbated by ingrown loose hairs into these sinuses (Hull 2002; Karydakis 1992) . In one Norwegian study, the estimated incidence of pilonidal sinus was 26 per 100,000 of the population (Søndenaa 1995). The mean age at consultation is 29 years in men and 25 years in women. Risk factors for development of the condition include male gender, extensive body hair, young adulthood, family history, local trauma, sedentary lifestyle, poor hygiene, an anatomically deep natal cleft and obesity (Akinci 1999; Søndenaa 1995; Thompson 2010) . Apart from the health considerations, there is also an economic implication for healthcare systems and society in managing this condition. The ideal management of pilonidal sinus disease should be simple, cost-effective, easy to perform and lead to a rapid return to normal activities, with low rates of infection and recurrence, and rapid wound healing. Acute presentation with pilonidal abscess is treated with simple incision and drainage. However, one patient in five will experience recurrent symptoms (Jensen 1988) . Chronic pilonidal sinus disease presents as recurrent episodes of infection, pain and discharge from the natal cleft. There is no consensus as yet on the management of pilonidal sinus disease, but all interventions are surgical and are split, in broad terms, into two strategies: excision without closure to allow healing through secondary intention (wound left open) or excision with primary closure (wound closed at the time of surgery). A Cochrane Review in 2010 showed that healing through secondary intention had lower recurrence rates compared with primary closure (risk ratio (RR) 0.65, 95% confidence interval (CI) 0.46 to 0.93) but at the expense of longer healing times (41 to 120 days in healing through secondary intention versus 10 to 27 days in primary closure) (Al-Khamis 2010). For people who undergo primary closure there is a clear benefit in terms of rates of recurrence if it is performed through off-midline closure (wound lying adjacent to the natal cleft) versus midline closure (wound lying within the natal cleft) (Enriquez-Navascues 2014). Commonly performed offmidline closure techniques include the Karydakis flap, Bascom II technique, and Rhomboid and Limberg flaps; however, the results are variable. Although these flap techniques have low recurrence and infection rates, they may lead to complications and significantly delayed return to employment (Thompson 2010).
Description of the intervention
Fibrin glue may offer an alternative to surgery in the definitive treatment of pilonidal sinus disease. The glue has been used for a variety of applications over the last 15 years (Spotnitz 2010), including anal fistulas (Sentovich 2003) , skin grafts (Currie 2001), and haemostasis (an intervention that stops the bleeding process) (Rutgeerts 1997). Treatment costs are dependent on volume and brand although treatment costs are typically low (approximately GBP 200 per treatment). The fibrin glue is composed of fibrinogen and thrombin, causing formation of a fibrin clot within the sinus. Studies suggest few complications (0% to 12.5%), low recurrence rates (0% to 17%) (Handmer 2012), early return to normal activities (Lund 2005; Patti 2006) , and high levels of patient satisfaction (Elsey 2013). However, these are often small observational studies and therefore conclusions are limited. Complications may include seromas and wound breakdown (Handmer 2012). Many previous studies have used fibrin glue as an adjunct to surgical treatment, for example, to close dead space (a cavity remaining after closure of a wound) in primary closure techniques. However, fibrin glue as monotherapy may be an alternative intervention to surgery for pilonidal sinus disease.
How the intervention might work
Thrombin within the glue mixture converts fibrinogen to fibrin, forming a fibrin clot within the sinus. Both thrombin and fibrin are normal blood products produced during the blood clotting process. This may reduce dead space within the sinus and promote healing without the need for invasive surgical excision and associated wound-healing complications, and thus allow a faster return to normal activities.
Why it is important to do this review
Consensus on the optimal treatment for pilonidal sinus disease is lacking. There are a wide variety of techniques, each with advantages and disadvantages. As found in a previous Cochrane review, more invasive procedures lead to less recurrence at the expense of delayed recovery time and slower healing (Al-Khamis 2010). Therefore, no current treatment satisfies the criteria for an ideal therapy for pilonidal sinus disease. Fibrin glue is a less invasive, novel monotherapy that has shown promise in observational studies. However, evidence from randomised controlled trials is required, as this is the optimum method to assess the effects of this intervention. Previous systematic reviews have included both observational studies and randomised controlled trials and no data from unpublished studies (Handmer 2012; Kayaalp 2016). Therefore, a rigorous summary of the evidence is required to determine whether fibrin glue should be more widely used for treating pilonidal sinus disease.
O B J E C T I V E S
To assess the effects of fibrin glue alone or in combination with surgery compared with surgery alone in the treatment of pilonidal sinus disease.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) only.
Types of participants
We included all ages of participants in the review. There was no restriction on the setting in which the treatment was delivered. We considered studies including both new and recurrent pilonidal sinus.
Types of interventions
Fibrin glue (any brand containing a mixture of fibrinogen and thrombin, human or bovine) compared with other surgical techniques such as primary closure, closure through secondary intention and off-midline closure techniques. We also included trials if they used fibrin glue as an adjunct to surgery (compared with surgery alone).
Types of outcome measures Primary outcomes
• Healing (time to wound healing in days) • Adverse events (seroma and allergic reaction).
Secondary outcomes
• Infection -surgical site infection (SSI) (proportion of pilonidal sinus surgical sites infected during follow-up as reported in the study)
• Recurrence -of treated pilonidal sinus as opposed to a new pilonidal sinus at another site (proportion of treated pilonidal sinus that recurred during follow-up as reported in the study)
• Postoperative or post-procedural pain (measured using a validated scale such as a visual analogue scale (VAS))
• Time to return to normal activities (days)
• Quality of life (measured using validated scales such as SF-36, EQ-5D or the Cardiff Wound Impact Schedule)
• Cost difference (of treatment, postoperative care and loss of employment in GBP or USD)
• Length of stay in hospital (days).
Search methods for identification of studies Electronic searches
We searched the following electronic databases to identify relevant RCTs:
• the Cochrane Wounds Specialised Register (searched 13 December 2016);
• • EU Clinical Trials Register.
Searching other resources
There was no language restriction in the search and, where necessary, we translated non-English language papers using Google Translate. We sought grey literature from OpenSIGLE. We searched conference proceedings from the last three years (Association of Coloproctology of Great Britain and Ireland, European Society of Coloproctology, Royal Society of Medicine Coloproctology Section and American Society of Colon and Rectal Surgeons). We handsearched reference lists of identified studies for other suitable papers. We utilised Google Scholar to identify papers that had cited identified studies.
Data collection and analysis
We conducted data analysis using Review Manager 5 (RevMan 5) (RevMan 2014) according to methods stipulated in the published review protocol (Lund 2015) .
Selection of studies
Two review authors independently matched studies to the inclusion and exclusion criteria (BD and JPW) and, if any disagreement existed, a third review author was consulted and we reached agreement by consensus. We extracted the titles and abstracts of potentially relevant studies onto an electronic database and these underwent full-text review with duplicates being removed. We used full-text reports to match against the inclusion and exclusion criteria. We used the kappa statistic to measure agreement during the selection process. We identified duplicate publications of the same studies by using author names, study location, intervention details and cohort dates. We planned to link any duplicate publications. As one review author had authored one of the included studies (JL), we performed selection of studies using two different authors to reduce bias.
Data extraction and management
Two review authors independently collected and extracted data into an electronic database (BD and ST). As one review author had authored one of the included studies, we performed data extraction using two different authors to reduce bias. We then compared the data and resolved discrepancies by checking the original study. We stored data on a password-protected computer. If any information was not reported, we contacted the study authors for further information.
Where possible we extracted the following data:
• bibliographic data including date of completion/ publication;
• country of origin;
• publication status of study;
• source of funding for trial;
• trial design;
• care setting;
• number of participants randomised to each trial arm and number included in final analysis;
• eligibility criteria and key baseline participant data including category(s) and location(s) of sinus;
• details of treatment regimen received by each group;
• duration of treatment;
• details of any co-interventions;
• primary and secondary outcome(s) (with definitions and, where applicable, time points);
• outcome data for primary and secondary outcomes (by group);
• duration of follow-up;
• number of withdrawals (by group) and number of withdrawals (by group) due to adverse events;
• adverse events.
Assessment of risk of bias in included studies
Two study authors (BD and ST) assessed risk of bias independently and a third author resolved any disagreements (JPW). We used the Cochrane tool for assessing risk of bias (Appendix 2; Higgins 2011a). We recorded sequence generation, allocation concealment, blinding of participants, personnel and outcome assessors, incomplete outcome data, selective outcome reporting and other sources of bias. We assigned each study low, high or unclear risk of bias using published criteria (Higgins 2011a). To assess selective outcome reporting, we searched clinical trials databases for the original study registration and compared this with the published study. In terms of blinding, we recognised that this would be difficult to implement fully as in other surgical studies. However, blinding of outcome assessment was deemed possible in studies comparing fibrin glue as an adjunct to surgery. We presented risk of bias data in a summary table and 'Risk of bias' graph.
Measures of treatment effect
We presented dichotomous outcomes as risk ratios (RR). We presented continuous outcomes as mean differences (MD) if scales were comparable or standardised mean differences (SMD) if noncomparable scales were used. We would have reported time-toevent data as hazard ratios (HR). If HR were not reported, we would have estimated these using the events in each group and derived the P value from the log rank test (Tierney 2007). Where time to healing was wrongly reported as a continuous outcome (as opposed to a time-to-event outcome) and we were not able to derive hazard ratios we endeavoured to find out whether all participants had healed and we planned to exclude such data from meta-analyses.
Unit of analysis issues
As the person was the unit of analysis and they are likely to have only one pilonidal sinus, there were no unit of analysis issues ( Higgins 2011b).
Dealing with missing data
If studies with missing data were identified, we contacted the study authors. If we received no response, we extracted data from published graphs if appropriate. If standard deviations were not reported, we estimated these from other studies in the review. We used the most clinically similar study to the one with missing values for these estimates. We did not use methods of imputation for missing participant data.
Assessment of heterogeneity
We assessed clinical heterogeneity during the data extraction process, especially the trial methods and baseline demographics. If significant clinical heterogeneity was present, we did not pool studies and discussed them in the narrative review. For statistical heterogeneity, we used the I 2 statistic (Higgins 2003). We pooled data using the fixed-effect model in the first instance. If substantial heterogeneity was present, we pooled data using the random-effects model. We used the following cut-off values for the I 2 statistic (Deeks 2011):
• 0% to 40%: might not be important;
• 30% to 60%: may represent moderate heterogeneity;
• 50% to 90%: may represent substantial heterogeneity;
• 75% to 100%: considerable heterogeneity.
Assessment of reporting biases
We assessed selective reporting bias as part of the Cochrane 'Risk of bias' tool. We planned to assess publication bias qualitatively using funnel plots and quantitatively using Egger's regression test if 10 studies or more were included in the analysis (Sterne 2011). However, the low number of included studies precluded this.
Data synthesis
We presented meta-analysis as forest plots if methods were similar enough that data synthesis was deemed appropriate. If not appropriate, we performed qualitative synthesis. We did not estimate missing data on measures of central tendency from reported values (mean estimated from median). We contacted study authors to provide any missing values. We combined continuous outcomes using generic inverse variance from the standard errors. We combined risk ratios using the Mantel-Haenszel method. We used a fixed-effect model if there was no heterogeneity. If heterogeneity was present, we used the random-effects model (Deeks 2011).
'Summary of findings' table
We have presented the main results of the review in 'Summary of findings' tables. These tables present key information concerning the quality of the evidence, the magnitude of the effects of the interventions examined, and the sum of the available data for the main outcomes (Schünemann 2011a). The 'Summary of findings' tables also include an overall grading of the evidence related to each of the main outcomes using the GRADE approach, which defines the quality of a body of evidence as the extent to which one can be confident that an estimate of effect or association is close to the true quantity of specific interest. The quality of a body of evidence involves consideration of within-trial risk of bias (methodological quality), directness of evidence, heterogeneity, precision of effect estimates and risk of publication bias (Schünemann 2011b). Evidence from RCTs is downgraded from high quality to moderate, low or very low quality if any of the above uncertainties are present. We have presented the following outcomes in the 'Summary of findings' tables:
• time to healing (days);
• adverse events (seroma and/or allergic reaction).
Subgroup analysis and investigation of heterogeneity
We planned to conduct subgroup analysis and meta-regression. However, the small number of included studies precluded this.
Sensitivity analysis
We planned to conduct a sensitivity analysis excluding studies that we judged high risk of bias for any of the 'Risk of bias' assessments and those sponsored by pharmaceutical companies. If sensitivity analysis results differed substantially, we would have carefully interpreted the final results.
R E S U L T S Description of studies
Results of the search
We identified 38 studies from searching of electronic databases ( Figure 1 ) and a further two records from searching clinical trials databases and conference proceedings. However, these were duplicate records from the same study (Lund 2010) . Further information was requested and provided from one of the review authors (JL). We considered four studies to be eligible for inclusion in the final review.
Included studies
We included four RCTs with 253 participants ( One study reported the following outcomes: drainage volume, length of stay, proportion of wounds infected, seroma (adverse event) and mortality (Altinli 2007). One unpublished study reported: pain, quality-of-life scores, analgesia usage, recurrence, infection, time to return to normal mobility and employment and cost reduction compared with surgery (Lund 2010). One study reported: length of stay, seroma and recurrence (Sözen 2011a). The final study reported: postoperative pain, time to first mobilisation, length of stay, time to return to employment, infection, flap oedema, wound dehiscence, seroma, healing time and duration of surgery (Sözen 2011b). Units of measurement can be found in the characteristics of included studies tables (Characteristics of included studies). Follow-up in the included studies were: mean 8.5 months and 8.2 months (intervention and control group respectively) (Altinli 2007), median 4.6 years (Lund 2010), median 10.2 months (Sözen 2011a) and mean 2 months and 6 months (intervention and control group respectively) (Sözen 2011b). The methods of outcome assessment were not reported in one study (Altinli 2007) . One study reported that a questionnaire was used to assess duration of recovery and that participants were followed up weekly until wounds had healed then every three months for one year (Sözen 2011b). One study followed up participants with physical examination at one month then six monthly thereafter (Sözen 2011a). One study measured outcomes at one and six weeks in clinic (Lund 2010). Due to the differences between the Karydakis and Limberg procedures, we did not pool data from these different surgical approaches together. The Karydakis procedure involves an off-midline elliptical incision, whilst the Limberg procedure involves a rhomboid incision with a flap constructed from an additional lateral incision. Moreover, previous research has shown differing outcomes for these surgical techniques making separate comparisons more clinically appropriate (Bali 2015).
Excluded studies
We excluded five studies that were not RCTs ( 
Risk of bias in included studies
We performed 'Risk of bias' assessments using the Cochrane tool for assessing risk of bias (Higgins 2011a). We regarded all the included studies as being at high risk of bias. The assessments for each study can found in Figure 2 and Figure 3 . Details on the criteria for assessing risk of bias can be found in Appendix 2. Two studies randomised participants on the basis of an admission protocol number and therefore were classified at high risk of bias for randomisation and unclear risk for allocation concealment, as there was not enough information to determine whether allocation of participants from this protocol number could be foreseen (Sözen 2011a; Sözen 2011b). One study randomised participants on the basis of the day they were first seen in clinic and therefore we regarded it as being at high risk of bias for both randomisation and allocation concealment (Altinli 2007). One study used computer-generated randomisation and allocated participants using sequentially-numbered, sealed opaque envelopes and therefore was assessed as low risk for both domains (Lund 2010).
Blinding
None of the included studies used a placebo substitute for fibrin glue. Two studies used postoperative drains in the control group but not the fibrin glue group and were therefore regarded as high risk for performance and detection bias (Sözen 2011a; Sözen 2011b). One study did not have differential use of postoperative drains although the care-giver was not blinded so we regarded at high risk for performance bias and unclear risk for detection bias, as no details were provided on outcome assessment (Altinli 2007). One study used fibrin glue monotherapy compared with surgery (Bascom's procedure) and therefore could not be blinded, so we classified it at high risk for performance and detection bias (Lund 2010).
Incomplete outcome data
Three studies did not report any participants lost to follow-up and therefore we regarded them to be at low risk of bias for this domain (Altinli 2007; Sözen 2011a; Sözen 2011b) . One study lost one participant to follow-up in the control group; this study was classified as low risk, as it was not thought this would significantly bias the results obtained (Lund 2010).
Selective reporting
Only one study registered on a clinical trials database and healing was pre-stated on registration although not reported in a published abstract so we regarded this as high risk of bias (Lund 2010). We could not identify any published clinical trials registration for the three other studies and we regarded all these as being at unclear risk of bias for this domain (Altinli 2007; Sözen 2011a; Sözen 2011b).
Other potential sources of bias
Three studies had similar baseline characteristics and no other risks of bias and therefore we classified them at low risk for this domain (Altinli 2007; Lund 2010; Sözen 2011a) . One study had different lengths of follow-up in the fibrin and control groups (mean followup two months and six months respectively) and therefore was classified at high risk for this domain (Sözen 2011b). This outcome was not reported in the included study. Further data showed that all wounds had healed at follow-up (median 11 months) although there were no data to calculate time to healing.
Effects of interventions
Adverse events
These outcomes were not reported in the included study.
Secondary outcomes
Infection
We included one unpublished study with 39 participants in this outcome (Lund 2010). It is uncertain whether there was a difference in infection rates at a median follow-up of 11 months with fibrin glue when compared with Bascom's procedure (RR 0.57, 95% CI 0.16 to 2.06) (Analysis 1.1). The quality of evidence was very low-quality according to GRADE (downgraded twice for risk of bias and for imprecision).
Recurrence
The same unpublished study (39 participants) reported this outcome (Lund 2010). It is uncertain whether there was a difference in the proportion of participants suffering a recurrence of their pilonidal sinus within a median follow-up period of 11 months (RR 0.95, 95% CI 0.06 to 14.13). The quality of evidence was very low (downgraded twice for risk of bias and for imprecision). It is also uncertain whether there was a difference on longer-term follow-up (median 4.6 years) in the same study (Lund 2010) (RR 1.43, 95% CI 0.27 to 7.61) (Analysis 1.2; very low-quality evidence downgraded twice for risk of bias and for imprecision).
Pain
The same unpublished study (39 participants) reported this outcome (Lund 2010). This study measured pain on an 11-point scale, from day one to day seven after the procedure however we report results from day one as this a standard time to measure pain in trials of postoperative analgesics. Fibrin glue may reduce pain on day one after the procedure (MD -2.50, 95% CI -4.03 to -0.97) (Analysis 1.3), measured on an 11-point scale. The quality of evidence was low (downgraded twice for risk of bias).
Time to return to normal activities
The same unpublished study (39 participants) reported this outcome (Lund 2010). Fibrin glue may reduce the time to return to employment compared with Bascom's procedure (MD -34.80 days, 95% CI -66.82 days to -2.78 days) (Analysis 1.4), however this finding is highly uncertain. The quality of evidence was very low (downgraded twice for risk of bias and for imprecision).
Quality of life
The same unpublished study (39 participants) reported this outcome (Lund 2010). It is uncertain whether fibrin glue leads to an improvement in quality of life at day seven, measured using the EQ-5D scale (MD 8.00, 95% CI -0.10 to 16.10) (Analysis 1.5). The quality of evidence was very low (downgraded twice for risk of bias and for imprecision).
Cost difference
The same unpublished study (39 participants) reported this outcome (Lund 2010). Non-reporting of standard deviations or costs in each group precluded inclusion in the analysis. The study reported a cost reduction of GBP 1120 (USD 1623) in the fibrin glue participants compared with participants in the Bascom's procedure group.
Length of stay
This outcome was not reported in the included study.
Limberg flap with and without fibrin glue (two RCTs, 164 participants)
Primary outcomes
Healing
One study (132 participants) reported this outcome (Sözen 2011b) as time to healing, albeit wrongly regarding time to healing as a continuous outcome. We were able to discern from the published data that all participants healed and therefore all contributed data to the analysis. Fibrin glue as an adjunct to Limberg flap may decrease the time to healing compared with Limberg flap with a suction drain (MD -13.95 days, 95% CI -16.76 days to -11.14 days) (Analysis 2.1) however this is highly uncertain. The quality of evidence was very low (downgraded twice for risk of selection, performance and detection bias and imprecision).
Adverse events
Two studies with 164 participants reported this outcome and they were pooled using a fixed-effect model (I 2 = 0%) (Altinli 2007; Sözen 2011b). It is uncertain whether using fibrin glue alongside the Limberg flap affected the incidence of seroma (RR 0.27, 95% CI 0.05 to 1.61) (Analysis 2.2). The quality of evidence was very low (downgraded twice for risk of selection, performance and detection bias and for imprecision). The incidence of allergic reactions was not reported in either study.
Secondary outcomes
Infection
The same two studies with 164 participants reported this outcome and their results were pooled using a fixed-effect model (I 2 = 0%) (Altinli 2007; Sözen 2011b). It is uncertain whether using glue alongside the Limberg flap affected the incidence of postoperative infection (RR 0.33, 95% CI 0.04 to 3.11) (Analysis 2.3). The quality of the evidence was very low (downgraded twice for risk of selection, performance and detection bias and for imprecision).
Recurrence
One study with 132 participants reported this outcome (Sözen 2011b) and found no cases of recurrence in either group.
Postoperative pain
The same study involving 132 participants reported this outcome (Sözen 2011b). Fibrin glue as an adjunct to the Limberg flap may decrease postoperative pain (measured on a 10 cm VAS on day one) compared with the Limberg flap and a suction drain (median score with glue as an adjunct was 2, median score without glue was 4; reported P < 0.001). The quality of evidence was low (downgraded twice for risk of selection, performance and detection bias).
Time to return to normal activities
The same study involving 132 participants reported this outcome (Sözen 2011b). Fibrin glue as an adjunct to Limberg flap may decrease the time taken to return to normal activities compared with Limberg flap and suction drain (median time with glue was 8 days versus 17 days without glue; reported P < 0.001). The quality of evidence was low (downgraded twice for risk of selection, performance and detection bias).
Quality of life
This outcome was not reported in either study.
Cost difference
Length of stay
Two studies involving 164 participants reported this outcome and results were pooled using a random-effects model (I 2 = 79%) ( Altinli 2007; Sözen 2011b). It is unclear whether using fibrin glue with the Limberg flap reduced length of hospital stay compared with the Limberg flap alone (MD -1.69 days, 95% CI -2.08 days to -1.29 days) (Analysis 2.4). The quality of evidence was very low (downgraded for unexplained heterogeneity and twice for risk of selection, performance and detection bias).
Karydakis flap with and without fibrin glue (one RCT, 50 participants) Primary outcomes
Healing
This outcome was not reported in the included study (Sözen 2011a).
Adverse events
It is unclear whether using fibrin glue alongside the Karydakis flap affected the incidence of seroma compared with Karydakis flap and postoperative drain (Sözen 2011a) (RR 3.00, 95% CI 0.67 to 13.46) (Analysis 3.1). The quality of evidence was very low (downgraded twice for risk of selection, performance and detection bias and for imprecision). The incidence of allergy was not reported in the included study.
Secondary outcomes Infection
Recurrence
The same study (50 participants) reported this outcome (Sözen 2011a). There was no incidence of recurrence in either group.
Postoperative pain
Time to return to normal activities
Quality of life
Cost difference
Length of stay
Fibrin glue used alongside the Karydakis flap may reduce hospital length of stay when compared with Karydakis flap and postoperative drain (Sözen 2011a) (mean length of stay 2 days with glue compared with 3.7 days without glue; reported P < 0.001). The quality of evidence was low (downgraded twice for risk of selection, performance and detection bias).
Sensitivity analysis
We were unable to conduct a sensitivity analysis as all the included studies were at high risk of bias. None of the included studies reported sponsorship by pharmaceutical companies.
Other analyses
We were unable to conduct analyses for publication bias or investigation of heterogeneity due to the low number of included studies.
A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Limberg flap plus fibrin glue compared with Limberg flap for pilonidal sinus 1 Downgraded three levels f or risk of bias (random isation and blinding, double downgrade) and im precision. 
D I S C U S S I O N
Summary of main results
Our review included four RCTs of fibrin glue (with or without surgery) compared with surgery alone for pilonidal sinus disease (Summary of findings for the main comparison; Summary of findings 2; Summary of findings 3). One study evaluated fibrin glue as monotherapy compared with Bascom's procedure for people with chronic pilonidal sinus disease (Lund 2010). This study was at high risk of bias for blinding and selective outcome reporting (healing). The study was unpublished and did not report any of our primary outcomes. Although requests for further data showed that all wounds had healed at follow-up, there were no data available with which to calculate time to healing. The study showed that fibrin glue may reduce pain on the first day after the procedure compared with surgery and may reduce time to return to normal activities and costs, however these findings are highly uncertain as the quality of evidence was low or very low. It is highly uncertain whether using glue compared with surgery affected the incidence of infection or recurrence at follow-up. Two studies evaluated fibrin glue as an adjunct to the Limberg flap compared with the Limberg flap alone in people with chronic pilonidal sinus disease (Altinli 2007; Sözen 2011b) . One of these studies also used a suction drain in the group without glue (Sözen 2011b). Both studies were at high risk of bias due to inadequate randomisation and blinding. Very low-quality evidence from one study (Sözen 2011b) suggested fibrin glue as an adjunct to Limberg flap may reduce time to healing but this is very uncertain due to the quality of the evidence (the second study did not report healing). It is unclear whether fibrin glue as an adjunct to the Limberg flap reduced the risk of seroma due to the very low-quality of evidence. Fibrin glue as an adjunct to the Limberg flap may reduce postoperative pain and time to return to normal activities although the quality of evidence was low. It is uncertain whether fibrin glue reduced length of stay when compared with Limberg flap only due to very low-quality of evidence. Furthermore, it is unclear whether fibrin glue affected the incidence of infection or recurrence due to the very low-quality of evidence. One study evaluated fibrin glue as an adjunct to Karydakis flap compared with Karydakis flap and postoperative drain in people with chronic pilonidal sinus disease (Sözen 2011a). This study was at high risk of bias for randomisation and blinding. This study did not report the primary outcome of time to healing. It is uncertain whether fibrin glue as an adjunct to Karydakis flap affected the incidence of seroma due to the very low-quality of the evidence. There were no incidences of recurrence in either group. Fibrin glue as an adjunct to the Karydakis flap may reduce length of stay although the quality of evidence was low.
Overall completeness and applicability of evidence
During our searches of databases we identified only four RCTs of fibrin glue (with or without surgery) versus surgery. We were able to obtain all the information required from one unpublished study and the only study which evaluated fibrin glue as monotherapy (Lund 2010) . However, the pre-stated outcome of healing rate was not reported in the conference abstract. We attempted to contact one author of two of the included studies for further data although we received no response (Sözen 2011a; Sözen 2011b). Therefore, we presented these outcomes as reported within the published report as median with a P value. We are unaware of any other studies that were not included in the review. In terms of external validity, three of the included studies within the review, which were all conducted in Turkey, evaluated the use of fibrin glue in men only (Altinli 2007; Sözen 2011a; Sözen 2011b) . Therefore, it is unclear how the results from these studies apply to women and those from outside this care setting. Although male sex is a risk factor for pilonidal sinus, there is no reason to believe the effects would be different in men and women. In addition, current studies did not include children and therefore the efficacy of fibrin glue in this group is unclear. Furthermore, three studies that evaluated fibrin glue as an adjunct to surgery excluded participants with recurrent disease, which may limit the applicability of the evidence to those with primary disease (Altinli 2007; Sözen 2011a; Sözen 2011b).
Quality of the evidence
For fibrin glue monotherapy, the quality of the evidence was low for pain following the procedure and very low for all other outcomes. For fibrin glue as an adjunct to Limberg flap, the quality of the evidence was low for postoperative pain and time to return to normal activities. However, the quality of evidence was very low for healing, adverse events, infection and length of stay. For fibrin glue as an adjunct to Karydakis flap, the quality of evidence was low for length of stay and very low for adverse events. Severe concerns over risk of bias in all studies evaluating fibrin glue resulted in double downgrading of evidence (Schünemann 2011b). We were only able to identify four small RCTs (the sample sizes ranged from 39 to 164) and therefore most results are highly imprecise. Two studies were at high risk of selection, performance and detection bias due to the use of randomisation from an admission protocol number and the use of postoperative drains which are highly visible (Sözen 2011a; Sözen 2011b). One of these studies also had differential lengths of follow up (Sözen 2011b). Another study was at high risk of selection bias because participants were allocated based on the day they were seen in clinic although participants were likely blinded to treatment allocation (Altinli 2007). Only one study could be fully assessed for selective outcome reporting as this trial was registered in a clinical trials database, how-ever the pre-specified outcome of healing rate was not reported (Lund 2010). This study was at high risk of bias for performance and detection bias although this would be difficult to address in a trial of surgery compared with a less invasive intervention, which may limit the quality of evidence derived from future studies in this area.
Potential biases in the review process
We used a wide ranging search strategy and were able to retrieve published and most unpublished data from the studies identified. One study author did not reply with further information from two studies (Sözen 2011a; Sözen 2011b), although we were still able to include data qualitatively. One potential bias in the review process was that one of the review authors (JL) was also the author of one of the included studies (Lund 2010). This may have introduced unconscious bias during risk of bias assessments and interpretation of the data from this study. We attempted to mitigate this as far as possible by performing risk of bias assessments in duplicate, not involving this particular review author in these assessments and undergoing thorough peer review to identify any inappropriate presentation of data or conclusions. Further sources of bias include the estimation of standard deviation values as these may not reflect those from the original data. Furthermore, our decision to input pain data from the first postoperative day may not reflect important differences in pain at other time points.
Agreements and disagreements with other studies or reviews
We are aware of two previous systematic reviews on fibrin glue therapy for chronic pilonidal sinus (Handmer 2012; Kayaalp 2016) . However, these reviews included both randomised and observational studies with no data from unpublished studies. In one of these reviews (Handmer 2012), in single group cohort studies, the mean time to return to normal activities was 11 days for fibrin glue (standard deviation 6 days) which is comparable with our results for fibrin glue monotherapy (Lund 2010). These observational studies suggested that the incidence of pilonidal sinus recurrence after fibrin glue was low (1 in 85 patients; average follow-up ranges from 4 to 23 months). We also observed a low incidence of recurrence in participants treated with fibrin glue (1 in 111 patients; average follow-up ranges from 2 to 11 months). Our review differs in only including RCTs which have strengths over single-group cohort studies, which were included in the previous systematic reviews (Handmer 2012; Kayaalp 2016).
A U T H O R S ' C O N C L U S I O N S Implications for practice
At present, the effects of fibrin glue, either as a monotherapy or as an adjunct to surgery, are uncertain due to the quality of the evidence. All the included studies were at risk of bias and included a low number of participants. Low-quality of evidence suggests fibrin glue monotherapy may be associated with less pain than surgery on the first post-procedural day although future research is required to confirm this. We are uncertain about the effects of fibrin glue as an adjunct to the Limberg flap on time to healing and adverse events due to the very low-quality of evidence. Fibrin glue may decrease postoperative pain and time to return to normal activities when used alongside the Limberg flap although the quality of evidence was low. We are uncertain about the effects of fibrin glue as an adjunct to the Karydakis flap on seroma formation; it may reduce length of stay relative to surgery alone however this is highly uncertain due to the low-quality of the evidence. Further, larger and higher quality randomised controlled trials (RCTs) are required to inform clinical practice and patient choice.
Implications for research
Future RCTs should be adequately powered with larger numbers of participants and follow-up, ideally for five years to capture recurrence. Future RCTs should measure and report clinically-important and patient-relevant outcomes such as time to healing, rates of recurrence, infection and pain. Future trials should ensure that robust randomisation and allocation concealment are performed and, wherever possible, blind participants and outcome assessors while ensuring low attrition to follow-up to improve internal validity over the studies published thus far.
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D I F F E R E N C E S B E T W E E N P R O T O C O L A N D R E V I E W
The protocol was not specific with regard to time of measurement of postoperative pain, therefore we presented the first measurement taken post procedure as is standard in trials of postoperative analgesics. In addition, we widened the inclusion criteria to include the use of fibrin glue as an adjunct to surgery since this is a related indication and the inclusion of these studies will not introduce bias. We also changed the title of the review for simplicity.
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